Treatment of HCV in individuals with decompensated cirrhosis

J Liver Res Disord Ther 2017, 3(4): 00059 hepatocellular carcinoma, and/or acute on chronic liver failure may develop and result in diminished quality of life and survival without liver transplantation. Effective antiviral therapy that results in sustained virological response (SVR) is the only strategy that positively alters the natural history of liver disease associated with HCV infection by reducing the frequency of hepatic decompensation, liver-related mortality, all-cause mortality, need for liver transplantation, and hepatocellular carcinoma [2]. Furthermore, SVR is also associated with improved quality of life and increased work productivity [3]. Licensure of new generation direct-acting antiviral agents (DAAs) revolutionized treatment of HCV infection, as these agents have very high virological efficacy, low frequency of severe adverse events (AEs), and overall high barrier to resistance.